choose content

Choose content

Enter keywords to create a newsletter
create account

Create account

Enter your registration information
set preferences

Set preferences

Set up your newsletter name, delivery and time zone preferences
Hint: Enter different keywords to generate new results.

Now you can:

  1. Search the news index.
  2. Browse more than 1 million newsletters by category.
  3. Use preset newsletters:
    • Baclofen

Baclofen Newsletter
  • Medically, you might be interested in…Back Pain 16 Apr 2024 09:07 GMT

    … reduced pain intensity after treatment with tolperisone (a … pregabalin and 14 other medicines compared with placebo. Increased … plus sustained release tramadol, baclofen, and paracetamol plus tramadol … higher quality randomised controlled trials of head-to-head …

  • 3 Biotech Stocks Gaining Altitude and Interest 10 Apr 2024 17:20 GMT

    … top biotech stocks BioMarin Pharmaceutical Inc. (BMRN), ANI Pharmaceuticals, Inc … Besides, U.S. FDA approvals surged by nearly … innovations in drug discovery and treatment repurposing, leading … annual sales for Baclofen Oral Suspension totaling approximately …

  • ANI Pharmaceuticals Announces the Launch of Baclofen Oral Suspension 09 Apr 2024 10:50 GMT

    … reference listed drug (RLD) Fleqsuvy®. "The launch of Baclofen Oral Suspension … generic prescription pharmaceutical products, including for diseases with high unmet medical need … the U.S. Food and Drug Administration (“FDA”) of the products we …

  • Traumatic Brain Injury Market Report 2032: Epidemiology Data, Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight 03 Apr 2024 14:15 GMT

    Pharmaceuticals, … Treatment Landscape Traumatic Brain Injury Treatment Market There are numerous treatmentdrugs, anticoagulants, anticonvulsants, antidepressants, diuretics, muscle relaxants, and stimulants. Antidepressant medicationsbiotech

  • Cerebral Palsy Market Report 2032: Epidemiology Data, Clinical Trails, Latest FDA, EMA, PDMA Approvals by DelveInsight 22 Mar 2024 18:30 GMT

    baclofen (ITB). Key Cerebral Palsy Companies: Neurocrine Biosciences, Teva Pharmaceuticals … Forecast Cerebral Palsy Drugs Uptake and … and personalized medicine for the treatment of patients … treatment market, visit @ Cerebral Palsy Clinical Trials

  • Tizanidine: Advances in Pharmacology & Therapeutics and Drug Formulations 21 Mar 2024 04:56 GMT

    … inappropriate medication use in older adults.3 Additionally, baclofen … the treatment of spasticity.38 Newly Identified Drug–Drug Interactions … similar to the tricyclic antidepressants, can cause the … translated into clinical trials and new drug approvals. MDM …

  • Nexus Pharmaceuticals Launches Baclofen Injection, USP 18 Mar 2024 18:09 GMT

    Today, Nexus Pharmaceuticals announced the launch of Baclofen Injection, USP. This sterile … 806-4606. About Nexus Pharmaceuticals, LLC: Nexus Pharmaceuticals LLC., a US- … drugs fulfill a critical unmet medical need and delivers dependable life-saving treatment

  • 2023 First Generic Drug Approvals 08 Mar 2024 22:36 GMT

    … Bulk Package B. Braun Medical, Inc. Calcium Gluconate … (Baclofen) Oral Suspension 6/8/2023 Treatment … refractory to other drugs 18 213267 Thalidomide … 47;0.064% Glenmark Pharmaceuticals LimitedGlenmark Pharmaceuticals Limited Enstilar (Calcipotriene …

  • FDA Clears IND for Vanda’s Antisense Agent VCA-894A in Charcot-Marie-Tooth Disease Type 2S 30 Jan 2024 21:06 GMT

    … and flexibility. When medically indicated, orthopedic surgery … synergistic combination of baclofen, naltrexone, and sorbitol … Pharmaceuticals receives FDA approval to proceed with investigational new drugtrial of PXT3003, the PREMIER trial, for the treatment

  • Neurotech to begin Phase I/II trial of NTI164 for cerebral palsy 29 Jan 2024 11:31 GMT

    … disability. NTI164 is a drug formulation derived from a … for the trial will be enrolled at Monash Medical Centre, with … trial will be registered on the Australian New Zealand Clinical Trials … “For first-line treatment with oral Baclofen, the actual evidence of …

Satisfied with the content?

Continue to create your account.